Drug intelligence / Profile preview

SHR-2002 + SHR-1316

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SHR-2002 + SHR-1316 is a combination therapy under clinical investigation for the treatment of advanced malignant tumors, including neoplasms and advanced esophageal squamous cell carcinoma. SHR-2002 is a novel immune checkpoint inhibitor that acts as a CD112 receptor antagonist and T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor, while SHR-1316 (also known as adebrelimab) is an anti-Programmed death-ligand 1 receptor (PD-L1) monoclonal antibody. The combination aims to enhance antitumor immune responses by simultaneously blocking multiple inhibitory pathways in the tumor microenvironment. Clinical trials have evaluated this combination for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced or metastatic cancers who have failed standard therapies[1][2][3][4][5][6].

Other names: adebrelimab (for SHR-1316)

Targets

NECTIN2 (Nectin cell adhesion molecule 2)PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)CD274 (Programmed cell death protein 1 ligand 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on SHR-2002 + SHR-1316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2002 + SHR-1316.

Explore the full profile